Overview
Australian clinical-stage biopharmaceutical company developing MDMA, psilocybin, and cannabis-derived therapeutics for mental health conditions with a data-driven clinical trial platform. They operate licensed clinics to generate real-world evidence for regulatory submissions.
More in Psychedelics
Latest industry news
Cala Health Launches Next-Generation TAPS Therapy Wearable Nationwide for Tremor and Parkinson's Patients
2026-10-11 · Product
A New Neurotech Startup Launches to Challenge Sam Altman's Merge Labs in the BCI Race
2026-10-10 · Industry
Butterfly Network Teams Up With Bridge Neurotech to Chase Ultrasound-Based Brain-Computer Interfaces
2026-10-09 · Industry
Paradromics Hits Four-Year Mark for Stable Neural Recording in Landmark BCI Durability Milestone
2026-10-08 · Research
Company details
Category
🍄 Psychedelics
Location
Perth, Australia
Funding
Public · ASX
Website
emyria.com.auListed
2026-06-15
Is this your company?
Claim this listing to add your logo, full description, team, and products. Premium listings get featured placement.
Claim & upgrade listingAdvertise
Reach neurotech professionals
Newsletter sponsorships, featured listings, and sponsored articles.
View packages →